Acquista Criptovalute
Paga con
USD
USD
Buy & Sell
Hot
Supports Visa, MasterCard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
Mercati
Trading
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Opzioni
Hot
Trade European-style Vanilla Options
Conto unificato
Massimizza l'efficienza del tuo capitale
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Guadagna
Lancia
CandyDrop
Raccogli le caramelle per guadagnare airdrop
Launchpool
Staking rapido, guadagna potenziali nuovi token
HODLer Airdrop
Fai holding GT e ottieni enormi airdrop gratuitamente
Pre-IPOs
tag
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investimento
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
Altro
Promozioni
AI
Altro
TradFi
WCTC S8
Rewards
ACN

Prezzo Accenture

ACN
$197,40
+$3,40(+1,75%)

*Data last updated: 2026-04-17 13:39 (UTC+8)

As of 2026-04-17 13:39, Accenture (ACN) is priced at $197,40, with a total market cap of $119,39B, a P/E ratio of 21,15, and a dividend yield of 3,28%. Today, the stock price fluctuated between $195,80 and $198,07. The current price is 0,81% above the day's low and 0,33% below the day's high, with a trading volume of 3,78M. Over the past 52 weeks, ACN has traded between $177,51 to $325,71, and the current price is -39,39% away from the 52-week high.

ACN Key Stats

Yesterday's Close$194,00
Market Cap$119,39B
Volume3,78M
P/E Ratio21,15
Dividend Yield (TTM)3,28%
Dividend Amount$1,63
Diluted EPS (TTM)12,45
Net Income (FY)$7,67B
Revenue (FY)$69,67B
Earnings Date2026-06-19
EPS Estimate3,68
Revenue Estimate$18,82B
Shares Outstanding615,43M
Beta (1Y)1.236
Ex-Dividend Date2026-04-09
Dividend Payment Date2026-05-15

About ACN

Accenture plc, a professional services company, provides strategy and consulting, interactive, and technology and operations services worldwide. The company offers application services, including agile transformation, DevOps, application modernization, enterprise architecture, software and quality engineering, data management, intelligent automation comprises robotic process automation, natural language processing, and virtual agents, and liquid application management services, as well as program, project, and service management services; strategy consulting services; critical data elements, data management and governance, data platform and architecture, product-based organization and skills, business adoption, and value realization services; engineering, and research and development digitization; smart connected product design and development; product platform engineering and modernization; product as-a-service enablement; products related to production and operations; autonomous robotics systems; the digital transformation of capital projects; and digital industrial workforce solutions. It also provides data-enabled operating models; technology consulting and artificial intelligence services; services related to talent and organization/human potential; digital commerce; infrastructure services, such as hybrid cloud, network, digital workplace and collaboration, service and experience management, infrastructure as code, and managed edge and IoT devices; cyber defense, applied cybersecurity, managed security, OT security, security strategy and risk, and industry security products; services related to technology innovation; and intelligent automation services. In addition, the company offers cloud, ecosystem, marketing, supply chain management, zero-based budgeting, customer experience, finance consulting, mergers and acquisitions, and sustainability services. Accenture plc was founded in 1951 and is based in Dublin, Ireland.
SectorTechnology
IndustryInformation Technology Services
CEOJulie T. Spellman Sweet
HeadquartersDublin,None,IE
Official Websitehttps://www.accenture.com
Employees (FY)779,00K
Average Revenue (1Y)$89,43K
Net Income per Employee$9,85K

Accenture (ACN) FAQ

What's the stock price of Accenture (ACN) today?

x
Accenture (ACN) is currently trading at $197,40, with a 24h change of +1,75%. The 52-week trading range is $177,51–$325,71.

What are the 52-week high and low prices for Accenture (ACN)?

x

What is the price-to-earnings (P/E) ratio of Accenture (ACN)? What does it indicate?

x

What is the market cap of Accenture (ACN)?

x

What is the most recent quarterly earnings per share (EPS) for Accenture (ACN)?

x

Should you buy or sell Accenture (ACN) now?

x

What factors can affect the stock price of Accenture (ACN)?

x

How to buy Accenture (ACN) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Hot Posts su Accenture (ACN)

PessimisticOracle

PessimisticOracle

19 ore fa
Just scrolling through today's most active call options and noticed some pretty heavy volume in a few names worth mentioning. APP had a bunch of action - like 35k contracts moved, which is almost half their daily average. The $450 call that expired back in February was where most people were trading, over 2600 contracts just in that one strike. Pretty wild volume for a single expiration. BBWI was right there too with similar intensity - 20k contracts trading, also hitting around 44% of their usual daily volume. Their $20 calls from that same February expiration got crushed with activity, 8600 contracts. You're seeing the same pattern across the board today. Then ACN jumped in with 24k contracts, and again it's the most active call options today concentrated in that $250 put strike from a couple months back. About 7200 contracts on that one alone. Honestly seeing this kind of concentrated volume on old expirations is always interesting - makes you wonder what's driving people to those specific strikes. When you see most active call options today this concentrated in expired or near-expired contracts, there's usually some story there.
0
0
0
0
CryptoFrontier

CryptoFrontier

04-16 09:16
Sigenergy Technology, a Shanghai-based energy storage systems maker, rose as much as 85% in its Hong Kong stock market debut on April 16, 2025, after raising HK$4.4 billion (US$561 million) in an initial public offering, according to Reuters. The stock opened at HK$581 (US$74) against its IPO price of HK$324.20 (US$41), marking a significant first-day premium. ## IPO Performance and Pricing Details Sigenergy sold 13.57 million shares in the offering. The public offering received 1,102.05 times subscription from retail investors, while the international institutional tranche was 31.2 times subscribed, according to IPO data reported by Reuters. Retail investors borrowed HK$358.6 billion (US$45.7 billion) to participate in the subscription, based on data from Futu Securities cited by the South China Morning Post. ## Company Background and Strategic Positioning Sigenergy was founded in 2022 by Xu Yingtong, a former Huawei Technologies executive who spent 23 years at Huawei and previously led its photovoltaic (solar power) and AI computing business divisions, according to the company's IPO prospectus. The company describes its mission as becoming the "Apple of the Energy World," focusing on AI-driven optimization of energy systems. The company's financial performance has accelerated sharply. Revenue rose from 58 million yuan (US$8.51 million) in 2023 to 9 billion yuan (US$1.32 billion) in 2025, representing growth of more than 150-fold over two years, according to the company's prospectus. Gross margin reached 50.1% in 2025. ## Product Portfolio and Market Position Sigenergy's primary product is SigenStor, a modular energy storage system that integrates five components: a solar inverter, a power conversion system (PCS) that converts electricity between different forms for storage and use, a battery pack, a direct current fast-charging module, and an energy management system (EMS) that uses software to control and optimize energy consumption, per the company's prospectus. The company holds a 28.6% share of the niche market for stackable distributed energy storage systems, according to market research firm Frost & Sullivan cited in the prospectus. The company reports that customers in markets such as Sweden have reduced average electricity costs by approximately 70% through optimized energy use enabled by the SigenStor system. ## Investor Demand and Capital Allocation Before the IPO, Sigenergy attracted cornerstone investors including Temasek Holdings, Singapore's state-owned investment company, and Goldman Sachs Asset Management, according to ACN Newswire reporting on the IPO. The strong subscription demand and cornerstone investor participation reflect confidence in the energy storage sector's growth trajectory. Sigenergy stated it will allocate the IPO proceeds toward research and development, marketing, after-sales services, production expansion, development of broader commercial and industrial storage products, and working capital, per the company's prospectus. ## Frequently Asked Questions **Q: What is Sigenergy's main product and how does it work?** Sigenergy's primary product is SigenStor, a modular "5-in-one" system that combines a solar inverter, power conversion system (PCS), battery pack, direct current fast-charging module, and energy management system (EMS) to optimize energy storage and consumption, according to the company's IPO prospectus. **Q: How much did Sigenergy raise in its Hong Kong IPO and what was the first-day performance?** Sigenergy raised HK$4.4 billion (US$561 million) in its April 16, 2025 Hong Kong IPO and surged 85% on its first day of trading, opening at HK$581 compared to its IPO price of HK$324.20, per Reuters reporting. **Q: Who founded Sigenergy and what is the company's market position?** Sigenergy was founded in 2022 by Xu Yingtong, a former Huawei executive with 23 years at the company, and holds a 28.6% market share in stackable distributed energy storage systems according to Frost & Sullivan research cited in the prospectus.
0
0
0
0
SelfRugger

SelfRugger

04-15 21:05
This is a paid press release. Contact the press release distributor directly with any inquiries. Genmab Files Annual Report with the U.S. Securities and Exchange Commission =========================================================================== Genmab A/S Wed, February 18, 2026 at 1:23 AM GMT+9 1 min read In this article: GMAB +1.53% GNMSF +0.65% Genmab A/S **Media Release** **COPENHAGEN, Denmark; February 17, 2026** * **Genmab filed Form 20-F for the financial year 2025 with the U.S. SEC** **Genmab A/S** **(Nasdaq:** **GMAB****)**** a****nnounced today that** **it has filed its Annual Report for the financial year 2025 on Form 20-F with the U.S. Securities and Exchange Commission (SEC), incorporating by reference parts of the Genmab A/S Annual Report 2025. **Both reports are available via the SEC’s website, www.sec.gov and Genmab’s website, www.genmab.com. **About Genmab**  Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients. Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X. **Contact:**         Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs T: +1 609 524 0065; E: mmp@genmab.com Andrew Carlsen, Vice President, Head of Investor Relations T: +45 3377 9558; E: acn@genmab.com _This Media Release contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on __www.genmab.com_ _and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings __with the U.S. Securities and Exchange Commission (SEC), which are available at __www.sec.gov__. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law._ Story Continues _Genmab A/S and/or its subsidiaries own the following trademarks: Genmab__®__; the Y-shaped Genmab logo__®__; Genmab in combination with the Y-shaped Genmab logo__®__; HuMax__®__; DuoBody__®__; HexaBody__®__; DuoHexaBody__®__, HexElect__®_ _and KYSO__®__._ Media Release no. 03 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 Genmab A/S Carl Jacobsens Vej 30 2500 Valby Denmark **Attachment** * 170226_i03_2025 20-F Filing Terms and Privacy Policy Privacy Dashboard More Info
0
0
0
0